The variant NM_058216.3:c.848C>T (p.Thr283Ile) in RAD51C is absent from all population databases (gnomAD v2.1, v4.1, and gnomAD-Canada), meeting PM2 at supporting strength.¹ The variant is a missense change not triggering PVS1. No alternative pathogenic missense at the same residue (PM5), no de novo observations (PS2/PM6), no functional studies (PS3/BS3), no case-control or prevalence data (PS4), no segregation data (PP1/BS4), and no patient phenotype data (PP4) are available.² In silico predictors are mixed: REVEL (0.308) is indeterminate, BayesDel (0.074) is in the benign range, and SpliceAI predicts no splice impact (0.00). Neither PP3 nor BP4 is met.³ The RAD51C Hereditary Breast, Ovarian and Pancreatic Cancer VCEP specification (v1.0.0, doc_id 1535377178) is in preparation and does not provide finalized criterion-specific rules. Assessment defaults to generic ACMG/AMP 2015 guidelines (PMID:25741868).⁴ Under generic ACMG/AMP 2015 combination rules, a single supporting pathogenic criterion (PM2) is insufficient to reach Likely Pathogenic. No benign criteria are met. The variant is classified as a Variant of Uncertain Significance (VUS).⁵